Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 7/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | CCKAR | P32238 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluvastatin SCHEMBL464787 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL2847 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL13501651 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL556754 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL6268460 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL23468028 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL2848 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL678274 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL2849 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL4295454 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007039784-A2 | A NOVEL CRYSTALLINE POLYMORPH OF FLUVASTATIN SODIUM AND PROCESS FOR PREPARING IT | WOCKHARDT LIMITED (IN) | 2007-04-12 | — | — | WO | claimed |
| EP-1634870-A1 | Process and intermediates for the selective synthesis of Fluvastatin | Zhejiang Hisun Pharmaceutical Co. Ltd. (CN) | 2006-03-15 | — | — | EP | claimed |
| WO-2005019170-A1 | NOVEL PROCESS FOR PREPARATION OF 7-[3-(4-FLUOROPHENYL)-1-(1-METHYLETHYL)-1H-INDOL-2-YL]-3, 5-DIHYDROXY-6-HEPTENOIC ACID SODIUM SALT | BIOCON LIMITED (IN) | 2005-03-03 | — | — | WO | claimed |
| US-10500241-B2 | Compositions comprising Siraitia grosvenori extracts and methods for the treatment of infection | CASCADE ESTATES LIMITED (MU) | 2019-12-10 | — | — | US | disclosed |
| US-20180318370-A1 | COMPOSITIONS COMPRISING SIRAITIA GROSVENORI EXTRACTS AND METHODS FOR THE TREATMENT OF INFECTION | AMALFI ADVISORS LLC (MU) | 2018-11-08 | — | — | US | disclosed |
| US-20150231190-A1 | COMPOSITIONS COMPRISING SIRAITIA GROSVENORI EXTRACTS AND METHODS FOR THE TREATMENT OF INFECTION | CASCADE ESTATES LTD (MU) | 2015-08-20 | — | — | US | disclosed |
| WO-2015024925-A1 | MODULATORS OF THE UNCONVENTIONAL SECRETORY PATHWAY FOR USE IN THE TREATMENT OF ALEXANDER DISEASE | RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN (DE) | 2015-02-26 | — | — | WO | disclosed |
| EP-2373609-B1 | USE OF AMPHIPHILIC COMPOUNDS FOR CONTROLLED CRYSTALLIZATION OF STATINS AND STATIN INTERMEDIATES | KRKA D D NOVO MESTO (SI) | 2013-10-16 | — | — | EP | disclosed |
| US-8349337-B1 | Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions | GANEDEN BIOTECH, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2419407-A1 | IMPROVED PROCESS FOR THE PREPARATION OF FLUVASTATIN AND SALTS THEREOF | Pharmathen S.A. (GR) | 2012-02-22 | — | — | EP | disclosed |
| EP-2327682-A1 | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates | KRKA, D.D., Novo Mesto (SI) | 2011-06-01 | — | — | EP | disclosed |
| EP-0547000-B1 | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound | NOVARTIS AG (CH) | 2000-02-02 | — | — | EP | disclosed |
| EP-0948320-A1 | PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF THE HMG-CoA REDUCTASE INHIBITOR FLUVASTATIN | Astra Aktiebolag (SE) | 1999-10-13 | — | — | EP | disclosed |
| WO-1999049877-A2 | METHODS FOR REDUCING CHOLESTEROL USING BACILLUS COAGULANS SPORES, SYSTEMS AND COMPOSITIONS | GANEDEN BIOTECH, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
| EP-0907639-A1 | POLYMORPHIC COMPOUNDS | Astra Aktiebolag (publ) (SE) | 1999-04-14 | — | — | EP | disclosed |
| WO-1998015264-A1 | PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF THE HMG-CoA REDUCTASE INHIBITOR FLUVASTATIN | ASTRA AKTIEBOLAG (SE) | 1998-04-16 | — | — | WO | disclosed |
| WO-1998015290-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING HMG-CoA REDUCTASE INHIBITORS, IN PARTICULAR FLUVASTATIN | ASTRA AKTIEBOLAG (SE) | 1998-04-16 | — | — | WO | disclosed |
| WO-1997049681-A1 | POLYMORPHIC COMPOUNDS | ASTRA AKTIEBOLAG (PUBL) (SE) | 1997-12-31 | — | — | WO | disclosed |
| EP-0547000-A1 | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound | SANDOZ LTD. (CH) | 1993-06-16 | — | — | EP | disclosed |
| US-4929437-A | Coenzyme Q10 with HMG-CoA reductase inhibitors | MERCK & CO., INC. (US) | 1990-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231190-A1 | COMPOSITIONS COMPRISING SIRAITIA GROSVENORI EXTRACTS AND METHODS FOR THE TREATMENT OF INFECTION | CD4, GYS2, GANC | HMGCR 53/4885CYP2C9 125/4885SIRT6 1769/4885 |
| US-20180318370-A1 | COMPOSITIONS COMPRISING SIRAITIA GROSVENORI EXTRACTS AND METHODS FOR THE TREATMENT OF INFECTION | GYS2, CD4, GANC | HMGCR 52/4885CYP2C9 127/4885SIRT6 1737/4885 |
| US-10500241-B2 | Compositions comprising Siraitia grosvenori extracts and methods for the treatment of infection | GYS2, CD4, GANC | HMGCR 52/4885CYP2C9 127/4885SIRT6 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.